QURE — uniQure N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590560 ·
Netherlands
Last close
$47.46
Market Cap
$3.29B
52W High
$50.47
52W Low
$24.00
ADV30
1,261,151
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,841,000 | 5,491,000 | -44,676,000 | -81,059,000 | 985,103,000 | 413,027,000 | 661,053,000 |
| Mar 2026 | 3,562,000 | 3,343,000 | -44,269,000 | -53,535,000 | 778,706,000 | 139,994,000 | 629,363,000 |
| Dec 2025 | 5,568,000 | 5,133,000 | -51,494,000 | -37,086,000 | 824,908,000 | 80,240,000 | 626,007,000 |
| Sep 2025 | 3,701,000 | 3,303,000 | -49,489,000 | -80,529,000 | 888,382,000 | 597,056,000 | 659,636,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-160,787,000
Investing CF
$-262,972,000
Financing CF
$584,350,000
CapEx
$-991,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.14
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,463,530,000
Inventory
$0
Receivables
$5,778,000
ST Investments
$397,308,000
EBIT TTM
$-185,479,000
Pretax Income TTM
$-245,170,000
Interest Exp TTM
$59,691,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,672,000
EBITDA
$-182,916,000
Free Cash Flow
$-77,580,000
Enterprise Value
$3,033,961,984
Total Cash
$810,334,976
Total Debt
$552,166,976
Shares Out
69,366,412
Trailing EPS
$-3.98
Book Value
$4.67
ROE
-157.6%
ROA
-15.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,098,000 | -187,827,000 | -198,971,000 | 824,908,000 | 626,007,000 | — | -177,963,000 |
| Dec 2024 | 27,119,000 | -182,180,000 | -239,556,000 | 556,536,000 | 563,288,000 | — | -182,728,000 |
| Dec 2023 | 15,843,000 | -282,486,000 | -308,478,000 | 831,689,000 | 624,019,000 | — | -145,929,000 |
| Dec 2022 | 106,483,000 | -144,246,000 | -126,789,000 | 704,964,000 | 228,955,000 | — | -145,060,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.03
Max Pain — expiry 2026-09-18
max pain strike: $40.00 · spot: $50.55 · call oi: 4,896 · put oi: 1,659
Expected Move to 2026-09-18:
±$10.70
(21.17%) —
implied range
$39.85 –
$61.25
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | $3.21B | $26.85 | — |
| MBX | MBX Biosciences, Inc. | $3.20B | $66.39 | — |
| IMNM | Immunome Inc. | $3.18B | $28.01 | — |
| ABCL | AbCellera Biologics Inc. | $3.44B | $10.61 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.11B | $24.78 | — |
News headlines (Yahoo Finance, 1h cache)
uniQure (QURE) Q2 2026 Earnings Call Transcript
2026-08-08 00:35 · Yahoo
uniQure NV (QURE) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Operational Challenges
2026-07-29 21:02 · Yahoo
AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says
2026-07-29 15:49 · Yahoo
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
2026-07-29 12:25 · Yahoo
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
2026-07-29 11:05 · Yahoo
uniQure to Announce Second Quarter 2026 Financial Results
2026-07-22 11:05 · Yahoo
uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise
2026-07-18 06:09 · Yahoo
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
2026-07-17 18:52 · Yahoo
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
2026-07-17 18:28 · Yahoo
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
2026-07-17 18:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.